Andros Pharmaceuticals Co (ROCO:6917) Debt-to-Equity : 0.06 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Debt-to-Equity?

Andros Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$5.10 Mil. Andros Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$22.02 Mil. Andros Pharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$471.11 Mil. Andros Pharmaceuticals Co's debt to equity for the quarter that ended in Dec. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Andros Pharmaceuticals Co's Debt-to-Equity or its related term are showing as below:

ROCO:6917' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.34 Max: 0.5
Current: 0.06

During the past 5 years, the highest Debt-to-Equity Ratio of Andros Pharmaceuticals Co was 0.50. The lowest was 0.06. And the median was 0.34.

ROCO:6917's Debt-to-Equity is ranked better than
69.94% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs ROCO:6917: 0.06

Andros Pharmaceuticals Co Debt-to-Equity Historical Data

The historical data trend for Andros Pharmaceuticals Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Debt-to-Equity Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.34

0.43

0.50

0.11

0.06

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			0.50	0.18	0.11	0.12	0.06

Competitive Comparison of Andros Pharmaceuticals Co's Debt-to-Equity

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Debt-to-Equity falls into.

Andros Pharmaceuticals Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Andros Pharmaceuticals Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.097	+	22.024)	/	471.107
	=	0.06

Andros Pharmaceuticals Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.097	+	22.024)	/	471.107
	=	0.06

Andros Pharmaceuticals Co (ROCO:6917) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Andros Pharmaceuticals Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines